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Abstract
Purpose—To determine the prevalence and prognostic value of mismatch repair (MMR) status
and its relation to BRAF mutation (BRAFMT) status in metastatic colorectal cancer (mCRC).
Experimental Design—A pooled analysis of four phase III studies in first-line treatment of
mCRC (CAIRO, CAIRO2, COIN and FOCUS) was performed. Primary outcome parameter was
the hazard ratio (HR) for median progression-free survival (PFS) and overall survival (OS) in
relation to MMR and BRAF. For the pooled analysis, Cox regression analysis was performed on
individual patient data.
Results—The primary tumors of 3063 patients were analyzed, of which 153 (5.0%) exhibited
deficient MMR (dMMR) and 250 (8.2%) a BRAFMT. BRAFMT was observed in 53 (34.6%) of
patients with dMMR tumors compared to 197 (6.8%) of patients with proficient MMR (pMMR)
tumors (p<0.001). In the pooled data set, median PFS and OS were significantly worse for patients
with dMMR compared to pMMR tumors (HR 1.33, 95% CI 1.12-1.57 and HR 1.35, 95% CI
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1.13-1.61, respectively), and for patients with BRAFMT compared to BRAF wild-type (BRAFWT)
tumors (HR 1.34, 95% CI 1.17-1.54 and HR 1.91, 95% CI 1.66-2.19, respectively). PFS and OS
were significantly decreased for patients with BRAFMT within the group of patients with pMMR,
but not for BRAF status within dMMR, or MMR status within BRAFWT or BRAFMT.
Conclusions—Prevalence of dMMR and BRAFMT in mCRC patients is low and both
biomarkers confer an inferior prognosis. Our data suggest that the poor prognosis of dMMR is
driven by the BRAFMT status.
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INTRODUCTION
Colorectal cancer (CRC) is a heterogeneous disease arising through different pathways.(1, 2)
Three molecular pathways are well known to be involved in the multistep process of
colorectal carcinogenesis, including the chromosomal instability (CIN) pathway, the mutator
pathway (microsatellite instability (MSI)), and the epigenetic instability pathway or CpG
island Methylator Phenotype (CIMP), the latter of which has substantial overlap with the
other two.
MSI is the result of a deficient DNA mismatch repair (dMMR) system. A germ line
mutation in one of the mismatch repair genes, most often MLH1 or MSH2, is the cause of
dMMR in patients with Lynch syndrome, which comprises 0.8–5% of all CRCs.(3) dMMR
is also observed in 10–20% of patients with sporadic CRC, of which the majority of dMMR
tumors are due to inactivation of MLH1 (~95%), caused by hypermethylation of the gene
promoter, with MSH2 and MSH6 accounting for a smaller percentage.(3-5) These dMMR
tumors have distinct features, such as origin in the proximal colon, prominent lymphocytic
infiltrate, poorly differentiated morphology, mucinous or signet ring differentiation(6) and
association with a favorable prognosis in early stage CRC(7). In metastatic CRC (mCRC)
the prevalence of dMMR is low (3.5%).(8, 9) This supports the hypothesis that dMMR
tumors have a reduced metastatic potential.(10, 11) Due to its lower frequency the
prognostic role of dMMR in mCRC has not been properly evaluated thus far.
The presence of a BRAF mutation (BRAFMT) in a dMMR tumor indicates a sporadic origin,
and essentially excludes a diagnosis of Lynch syndrome.(12, 13) In CRC the overall
prevalence of BRAFMT is ~10%.(14) BRAFMT has a negative prognostic impact, although
this may be restricted to patients with proficient MMR (pMMR) tumors.(15, 16) Data on the
role of BRAF in relation to MMR status in mCRC are scarce and are derived from small
subsets of selected patients.
The current study was initiated to assess the role of MMR in relation to the BRAFMT status
in respect to prevalence and outcome in patients with mCRC who participated in four large
prospective phase III studies: CAIRO(17), CAIRO2(18), COIN(19, 20) and FOCUS(21).
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MATERIAL AND METHODS
Patients and treatment
Data were derived from mCRC patients included in four large phase III studies in first line
treatment: CAIRO (ClinicalTrials.gov NCT00312000), CAIRO2 (ClinicalTrials.gov
NCT00208546), COIN (ISRCTN 27286448) and FOCUS (ISRCTN 79877428), of which
the results have been published previously.(17-21) Collection of formalin-fixed paraffin-
embedded material (FFPE) of the primary tumor was part of the initial protocol in all four
studies.
MMR status
For samples of both CAIRO studies, immunohistochemistry (IHC) was performed on FFPE
tissue with antibodies against MMR proteins MLH1, MSH2, MSH6 and PMS2. In addition,
MSI analysis was performed where there was an absence of MMR protein expression or
equivocal IHC results. dMMR status was determined using two microsatellite markers (BAT
25 and BAT 26). If only one of these markers showed instability, the analysis was extended
with four additional markers (BAT 40, D2S123, D5S346, and D17S250). A tumor was
defined as dMMR if at least two of the six markers showed instability or pMMR if none of
the markers showed instability. Tumors with only one of the markers showing instability
were defined as dMMR-low and included in the pMMR category. For samples from the
COIN study, dMMR status was assessed using two microsatellite markers (BAT25 and
BAT26). If only one of these markers showed instability the tumor was defined as dMMR,
and as pMMR if no instability was observed. For samples from the FOCUS study, dMMR
status was based on loss of MLH1 and MSH2 protein expression, assessed by IHC. If either
protein showed loss of expression, the tumor was defined as dMMR, and pMMR if no loss
of expression was observed.
Hypermethylation status of the MLH1 gene promoter
Hypermethylation of the MLH1 gene promoter in patients with a dMMR tumor was
analyzed in samples from the CAIRO and CAIRO2 studies only and therefore not included
in the pooled analysis. The DNA methylation status of the MLH1 promoter region was
determined after bisulphite treatment of the DNA using the EZ DNA methylation KIT,
ZYMO Research (Orange, CA, USA), as described previously.(8)
BRAF mutation status
The BRAF V600E mutation status was assessed in duplicate by high resolution melting
(HRM) sequencing analysis for tumor material in the CAIRO study(22) and by direct
sequencing analysis in the CAIRO2 study(23). For samples of the COIN and FOCUS
studies, the BRAF V600E mutation status was determined by Pyrosequencing (and
Sequenom in COIN), and verified by Sanger sequencing as described previously.(19, 24)
Non-V600E BRAF mutations detected by these assays (n=19) were not included in the
current analyses on outcome.
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Statistical methods
Individual patient data were included in the pooled analysis. Progression free survival (PFS)
was defined as the time from the date of randomization to first progression or death,
whichever came first. Overall survival (OS) was defined as the time from randomization to
the date of death. The primary outcome measure was the hazard ratio (HR) for PFS and OS
in relation to MMR and BRAF mutation status. For PFS and OS all studies were included in
a Cox regression model (proportional hazard model) by using the study as a factor in the
model. In this way, dependence of the hazard on study could be modeled. The HR was
corrected for study effect. Survival curves were plotted and log-rank tests were performed to
compare survival for the different groups defined. A statistical interaction analysis for
survival data of dMMR and BRAF status was performed. All analyses were conducted using
the SAS system version 9.2; p <0.05 was considered as statistically significant.
RESULTS
Study population and MMR / BRAF mutation status
Tumor and normal samples from 3063 out of 6155 randomized mCRC patients were
available and suitable for analysis of both MMR and BRAF mutation status. Of these 3063
patients, 322 patients participated in the CAIRO study, 516 patients in the CAIRO2 study,
1461 patients in the COIN study and 764 patients in the FOCUS study.
The prevalence of MMR status and BRAF mutation status and their correlation are presented
in Table 1 and 2, respectively. dMMR was found in tumors of 153 (5.0%) patients and 250
(8.2%) patients had a BRAFMT (Table 1). There was no evidence of heterogeneity for the
prevalence of dMMR and BRAFMT in the four studies; p=0.614 and p=0.943, respectively
(Table 1). A BRAFMT was observed in 53 (34.6%) of patients with dMMR tumors compared
to 197 (6.8%) of patients with pMMR tumors (p<0.001) (Table 2). There was heterogeneity
for the prevalence of combined MMR and BRAFMT status between the four studies. In the
CAIRO study, there were significantly more patients with a combined dMMR and BRAFMT
(dMMR / BRAFMT) tumor compared to the other three studies (p=0.002) (Table 2).
Patient and tumor characteristics (sex, age, location of the primary tumor, performance
status, number of metastatic sites involved) for the different subgroups defined by the
combined MMR and BRAF mutation status are summarized in Supplementary Table 1.
Hypermethylation of MLH1 was the main cause of dMMR in both CAIRO and CAIRO2
studies (30 out of 45 patients), this was associated with a high frequency of BRAFMT (73%)
compared to tumors without MLH1 hypermethylation (7%).
Survival data
The survival data of the individual studies, the pooled data set and the pooled analysis for
patients with dMMR, pMMR, BRAFMT and BRAFWT tumors are presented in Table 3. The
median PFS and OS were significantly worse for patients with dMMR compared to pMMR
tumors (PFS: 6.2 versus 7.6 months, respectively, HR 1.33, 95% CI 1.12-1.57, p=0.001; OS:
13.6 versus 16.8 months, respectively, HR 1.35, 95% CI 1.13-1.61, p=0.001). Median PFS
and OS were also significantly worse for patients with BRAFMT compared to BRAFWT
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tumors (PFS: 6.2 versus 7.7 months, respectively, HR 1.34, 95% CI 1.17-1.54, p<0.001; OS:
11.4 versus 17.2 months, respectively, HR 1.91, 95% CI 1.66-2.19, p<0.001).
To determine a possible interaction between MMR and BRAF status, with respect to the
survival, a Cox regression was performed by using the study as a factor in the model. For
PFS and OS all studies were included in a Cox regression model (proportional hazard
model) by using the study as a factor in the model. Results are presented for MMR status in
a BRAFMT and BRAFWT background, and vice versa for BRAF status in a dMMR and
pMMR background in table 4. Survival curves, as estimated by the Cox regression, are
presented in Figure 1. In BRAFMT tumors stratified by MMR status, there was no significant
survival difference for patients with dMMR compared to pMMR tumors (PFS; 6.1 versus
6.2 months, respectively, HR 0.95, 95% CI 0.62-1.46, p=1.000; OS; 11.7 versus 11.3
months, respectively, HR 1.05, 95% CI 0.68-1.63, p=1.000). Also in BRAFWT tumors
stratified by MMR status, there was no significant survival difference for patients with
dMMR compared to pMMR tumors (PFS: 6.3 versus 7.8 months, respectively, HR 1.32,
95% CI 1.00-1.75, p=0.051; OS: 15.0 versus 17.3 months, respectively, HR 1.22, 95% CI
0.91-1.65, p=0.463). In dMMR tumors stratified by BRAF status, there was no significant
survival difference for patients with BRAFMT compared to BRAFWT tumors (PFS: 6.1
versus 6.3 months, respectively, HR 1.07, 95% CI 0.67-1.70, p=1.000; OS: 11.7 versus 15.0
months, respectively, HR 1.51, 95% CI 0.93-2.46, p=0.155). In pMMR tumors stratified by
BRAF status, there was a significantly decreased median PFS and OS for patients with
BRAFMT compared to BRAFWT tumors (PFS: 6.2 versus 7.8 months, respectively, HR 1.34,
95% CI 1.10-1.64, p<0.001; OS: 11.3 versus 17.3 months, respectively, HR 1.94, 95% CI
1.57-2.40, p<0.001) The test for interaction between dMMR and BRAFMT was statistically
not significant (PFS: HR 0.79, 95% CI 0.54-1.16, p=0.234; OS: HR 0.78, 95% CI 0.52-1.15,
p=0.211).
DISCUSSION
This study presents the largest data set on the role of tumor MMR status and BRAF mutation
status in respect to prevalence and outcome in a population of patients (n=3063) with mCRC
who participated in four prospective phase III studies. We found that dMMR and BRAFMT
in mCRC each have a low prevalence (5% and 8.2%, respectively), and that both biomarkers
indicate a poor prognosis. Given the absence of a statistically significant interaction between
BRAFMT and dMMR, our data suggest that the poor prognostic value of dMMR is driven by
the BRAFMT status.
Several aspects of our study warrant further discussion. In this pooled analysis different
methods for detecting dMMR were applied, which however have all been validated for the
detection of dMMR in CRC. In both CAIRO studies, an approach based on test methods
described in the Bethesda criteria, used for standard clinical practice for patients suspected
for Lynch syndrome, has been applied.(25) The COIN study analyzed the BAT25 and
BAT26 mononucleotide markers, which have a high sensitivity (94%) and specificity (98%),
and the use of these two markers alone identifies 97% of MSI tumors.(26) The FOCUS
study evaluated MLH1 and MSH2 protein expression by immunohistochemistry, which is a
sensitive (92.3%) and specific (100%) method for screening for dMMR.(27)
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We acknowledge that the difference in MMR detection methods represents a weakness of
our study, however the comparable prevalence of the dMMR status among the four studies
in this pooled analysis, ranging from 4.4% to 5.6% argues against this. The results from the
individual studies show that the patient population with dMMR tumors is heterogeneous.
The observed difference in the prevalence of a BRAFMT in dMMR tumors suggests a
possible difference in the origin of dMMR, sporadic versus hereditary. Unfortunately, data
on the hypermethylation status of the MLH1 gene promoter, which could differentiate
between these two groups, are not available of all four studies.
Furthermore, different methods for detecting the BRAF V600E mutation were applied. HRM
sequencing, Sanger sequencing and Pyrosequencing have all shown to be reliable
methods(22, 28). Data from systematic studies to assess the test accuracy or reproducibility
of the different techniques used for BRAF mutation testing are not available.
Another issue is the difference in availability of tumor samples among the trials. This is
partly caused by non-availability of an extra paraffin-embedded block for DNA analysis,
and partly due to non-resected primary tumors in patients with synchronous disease. In these
patients often only a diagnostic biopsy was performed, which does not provide sufficient
material for further molecular analysis for research purposes. This is an important,
underexposed issue which may introduce a sample/case bias not only in our analysis, but in
other translational studies in mCRC as well.
The low prevalence of dMMR in mCRC can be explained by the reduced potential of stage
I-III dMMR tumors to metastasize.(10, 11) However the underlying mechanisms of this low
metastatic potential are yet to be elucidated. It has been suggested that a greater
immunoreactivity of dMMR tumors(29, 30) or decreased tumor cell viability due to
excessive DNA damage(31) may play a role. In mCRC, data about the prevalence of
BRAFMT in dMMR tumors are scarce, but in line with our results.(32, 33) The strong inter-
relationship between BRAFMT and dMMR is well established in early stage CRC(14, 34),
however the etiology of both alterations still needs to be elucidated.
We observed a higher prevalence of BRAFMT in mCRC dMMR tumors (34.6%) than
reported for early-stage dMMR CRC tumors (24%).(16) Patients with early-stage dMMR in
general have a better prognosis compared to patient with early-stage pMMR, however
within the group of dMMR, patients with BRAFMT tumors have a worse prognosis.(35)
Subsequently, this may lead to a shift in the dMMR / BRAFMT ratio in mCRC patients.
There is increasing evidence identifying BRAFMT as a significant poor prognostic factor in
early stage and mCRC.(18, 36-38) BRAF is an oncogene and it is known that the mutations
constitutively activate the MAPK pathway for cell growth, in the absence of extracellular
stimuli. However, by itself BRAF is not sufficient for cancer and must cooperate with other
processes to induce the fully cancerous state.(39) Another explanation for the inferior
prognosis of BRAFMT tumors might be their distinct pattern of metastatic spread. Previous
studies have demonstrated a significantly increased rate of peritoneal and distant lymph
node metastases and a decreased rate of lung metastases compared to BRAFWT tumors.(9,
40)
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It has been speculated that the worse prognostic value of dMMR tumors in mCRC may be
related to a difference in metastatic spread. Earlier studies showed a reduced rate of liver
metastases for dMMR tumors in mCRC(40), and a higher incidence of peritoneal
metastases, these factors are known to be related to prognosis.(41, 42) This was confirmed
by a previous analysis of the COIN study (9), but these data are not available from the other
studies of our analysis.
Lastly, due to the different treatment regimens among the four studies of this pooled
analysis, the predictive role of dMMR and BRAFMT in mCRC could not be addressed.
In conclusion, dMMR and BRAFMT each have a low prevalence in mCRC, and both
biomarkers confer a poor prognosis. Our data suggest that the poor prognosis of dMMR is
driven by the BRAFMT status. However, we caution against a firm conclusion on this issue
since our study was not sufficiently powered to test this interaction.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Statement of translational relevance
This is the first pooled analysis on individual patient data to assess the role of the
mismatch repair (MMR) status in relation to the BRAF mutation status in respect to
prevalence and outcome in patients with metastatic CRC (mCRC). These patients
participated in four large randomized prospective phase III studies, namely the CAIRO,
CAIRO2, COIN and FOCUS studies. We show that the prevalence of deficient MMR
(dMMR) and BRAF mutation is low in mCRC patients. Both biomarkers confer an
inferior prognosis. We observed a higher incidence of BRAF mutation in dMMR tumors
than reported for early-stage dMMR CRC patients and our data suggest that the poor
prognosis of dMMR is driven by BRAFMT status.
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Figure 1. Progression-free (A) and overall survival (B) curves of all patients included in the
pooled data set comparing patients with dMMR / BRAFMT tumors, dMMR / BRAFWT tumors,
pMMR / BRAFMT tumors and pMMR / BRAFWT tumors
Venderbosch et al. Page 12
Clin Cancer Res. Author manuscript; available in PMC 2015 April 15.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Venderbosch et al. Page 13
Table 1
Prevalence of MMR and BRAF mutation status in patients with mCRC subdivided by
study
dMMR pMMR total BRAF MT BRAF WT total
CAIRO 18 (5.6%) 304 (94.4%) 322 25 (7.8%) 297 (92.2%) 322
CAIRO2 29 (5.6%) 487 (94.4%) 516 45 (8.7%) 471 (91.3%) 516
COIN 65 (4.4%) 1396 (95.6%) 1461 120 (8.2%) 1341 (91.8%) 1461
FOCUS 41 (5.4%) 723 (94.6%) 764 60 (7.9%) 704 (92.1%) 764
Pooled data set 153 (5.0%) 2910 (95.0%) 3063 250 (8.2%) 2813 (91.8%) 3063
p value 0.614 0.943
NOTE: Statistically significant results are set in bold
p values represent heterogeneity between the four studies
Abbreviations: dMMR = deficient mismatch repair, pMMR = proficient mismatch repair, mt = mutant tumors, wt = wild-type tumors
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Table 2
Prevalence of BRAF mutation status stratified for MMR status, and MMR status stratified for BRAF status in mCRC patients subdivided
by study
BRAF MT BRAF WT dMMR pMMR
dMMR pMMR total dMMR pMMR total BRAF MT BRAF WT total BRAF MT BRAF WT total
CAIRO 12 (48.0%) 13 (52.0%) 25 6 (2.0%) 291 (98.0%) 297 12 (66.7%) 6 (33.3%) 18 13 (4.3%) 291 (95.7%) 304
CAIRO2 12 (26.7%) 33 (73.3%) 45 17 (3.6%) 454 (96.4%) 471 12 (41.4%) 17 (58.6%) 29 33 (6.8%) 454 (93.2%) 487
COIN 20 (16.7%) 100 (83.3%) 120 45 (3.4%) 1296 (96.6%) 1341 20 (30.8%) 45 (69.2%) 65 100 (7.2%) 1296 (92.8%) 1396
FOCUS 9 (15.0%) 51 (85.0%) 60 32 (4.5%) 672 (95.5%) 704 9 (22.0%) 32 (78.0%) 41 51 (7.1%) 672 (92.9%) 723
Pooled data set 53 (21.2%) 197 (78.8%) 250 100 (3.6%) 2713 (96.4%) 2813 53 (34.6%) 100 (65.4%) 153 197 (6.8%) 2713 (93.2%) 2910
p value 0.002 0.239 0.007 0.330
NOTE: Statistically significant results are set in bold
p values represent heterogeneity between the four studies
Abbreviations: dMMR = deficient mismatch repair, pMMR = proficient mismatch repair, mt = mutant tumors, wt = wild-type tumors
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Table 3
Individual study data, pooled data set and pooled analysis of survival data in relation to MMR and BRAF mutation status
dMMR pMMR BRAF MT BRAF WT
CAIRO
PFS
number of patients 18 304 25 297
mo. (95% CI) 5.7 (4.2-8.8) 6.9 (6.2-7.9) 5.1 (4.1-7.7) 7.0 (6.3-8.2)
HR (95% CI) 1.34 (0.81-2.22) 1.57 (1.03-2.38)
OS
mo. (95% CI) 14.8 (12.0-26.0) 17.9 (16.1-19.2) 11.3 (8.3-15.0) 18.1 (16.2-19.4)
HR (95% CI) 1.26 (0.74-2.16) 2.20 (1.43-3.38)
CAIRO2
PFS
number of patients 29 487 45 471
mo. (95% CI) 7.5 (6.4-10.5) 10.5 (9.6-11.4) 6.9 (6.2-8.5) 10.6 (9.7-11.8)
HR (95% CI) 1.66 (1.13-2.45) 2.03 (1.48-2.79)
OS
mo. (95% CI) 15.6 (12.9-22.3) 22.0 (20.3-24.1) 13.1 (10.7-16.5) 22.4 (21.0-24.9)
HR (95% CI) 1.60 (1.07-2.40) 2.30 (1.65-3.20)
COIN
PFS
number of patients 65 1396 120 1341
mo. (95% CI) 5.7 (5.4-6.1) 6.5 (6.2-6.8) 5.8 (5.6-6.2) 6.5 (6.3-6.9)
HR (95% CI) 1.56 (1.20-2.02) 1.38 (1.14-1.68)
OS
mo. (95% CI) 10.7 (9.3-13.0) 16.0 (15.0-16.9) 10.2 (9.0-11.7) 16.5 (15.3-17.1)
HR (95% CI) 1.80 (1.37-2.37) 2.02 (1.65-2.48)
FOCUS
PFS
number of patients 41 723 60 704
mo. (95% CI) 8.1 (6.5-9.1) 8.0 (7.4-8.3) 8.1 (6.8-8.9) 8.0 (7.4-8.3)
HR (95% CI) 0.98 (0.71-1.35) 0.98 (0.74-1.28)
OS
mo. (95% CI) 16.6 (13.6-21.7) 15.5 (14.5-16.6) 12.3 (10.5-14.8) 15.7 (14.8-17.0)
HR (95% CI) 0.90 (0.64-1.27) 1.52 (1.15-2.00)
Pooled data set
PFS
number of patients 153 2910 250 2813
mo. (95% CI) 6.2 (5.9-7.0) 7.6 (7.3-8.0) 6.2 (6.0-6.8) 7.7 (7.4-8.0)
HR (95% CI) 1.33 (1.12-1.57) 1.34 (1.17-1.54)
OS
mo. (95% CI) 13.6 (12.4-15.6) 16.8 (16.3-17.5) 11.4 (10.5-12.4) 17.2 (16.7-18.0)
HR (95% CI) 1.35 (1.13-1.61) 1.91 (1.66-2.19)
NOTE: Statistically significant results are set in bold
Abbreviations: PFS = progression-free survival, OS = overall survival, mo. = median PFS and OS time in months, HR = hazard ratio, CI = confidence interval, dMMR = deficient mismatch repair, pMMR
= proficient mismatch repair, mt = mutant tumor, wt = wild-type tumor
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Table 4
Individual study data, pooled data set and pooled analysis of survival data and association between MMR and BRAF mutation status
BRAF MT BRAF WT dMMR pMMR
dMMR pMMR dMMR pMMR BRAF MT BRAF WT BRAF MT BRAF WT
CAIRO
PFS
number of patients 12 13 6 291 12 6 13 291
mo. (95% CI) 6.6 (4.6-12.6) 4.1 (2.4-6.4) 3.6 (2.0-16.4) 7.1 (6.4-8.2) 6.6 (4.6-12.6) 3.6 (2.0-16.4) 4.1 (2.4-6.4) 7.1 (6.4-8.2)
HR (95% CI) 2.38 (0.80-7.09) 3.19 (0.96-10.63) 0.34 (0.08-1.44) 2.60 (1.21-5.55)
OS
mo. (95% CI) 13.2 (10.1-28.6) 8.3 (5.9-13.6) 18.6 (12.4-53.5) 18.2 (16.2-19.4) 13.2 (10.1-28.6) 18.6 (12.4-53.5) 8.3 (5.9-13.6) 18.2 (16.2-19.4)
HR (95% CI) 2.14 (0.70-6.54) 0.97 (0.25-3.57) 1.63 (0.34-7.77) 3.29 (1.53-7.04)
CAIRO2
PFS
number of patients 12 33 17 454 12 17 33 454
mo. (95% CI) 5.7 (4.4-8.5) 7.5 (6.4-9.7) 9.3 (7.2-14.8) 10.7 (9.9-12.1) 5.7 (4.4-8.5) 9.3 (7.2-14.8) 7.5 (6.4-9.7) 10.7 (9.9-12.1)
HR (95% CI) 0.54 (0.22-1.34) 1.25 (0.62-2.49) 2.65 (0.95-7.41) 1.79 (1.09-2.93)
OS
mo. (95% CI) 10.4 (7.8-17.2) 14.1 (11.5-19.4) 21.0 (15.2-36.4) 22.4 (21.1-25.0) 10.4 (7.8-17.2) 21.0 (15.2-36.4) 14.1 (11.5-19.4) 22.4 (21.1-25.0)
HR (95% CI) 0.61 (0.25-1.52) 1.14 (0.54-2.40) 2.94 (1.02-8.52) 2.04 (1.21-3.44)
COIN
PFS
number of patients 20 100 45 1296 20 45 100 1296
mo. (95% CI) 5.9 (5.4-8.5) 5.8 (5.6-6.2) 5.6 (5.1-6.1) 6.6 (6.3-7.0) 5.9 (5.4-8.5) 5.6 (5.1-6.1) 5.8 (5.6-6.2) 6.6 (6.3-7.0)
HR (95% CI) 1.05 (0.53-2.11) 1.72 (1.14-2.60) 0.78 (0.37-1.66) 1.42 (1.07-1.88)
OS
mo. (95% CI) 10.5 (8.2-16.3) 10.2 (8.9-11.8) 10.8 (9.2-14.0) 16.7 (15.6-17.5) 10.5 (8.2-16.3) 10.8 (9.2-14.0) 10.2 (8.9-11.8) 16.7 (15.6-17.5)
HR (95% CI) 1.04 (0.52-2.10) 1.85 (1.19-2.88) 1.08 (0.50-2.34) 2.07 (1.54-2.79)
FOCUS
PFS
number of patients 9 51 32 672 9 32 51 672
mo. (95% CI) 6.8 (4.9-12.0) 8.3 (6.8-9.1) 8.3 (6.8-9.6) 8.0 (7.4-8.3) 6.8 (4.9-12.0) 8.3 (6.8-9.6) 8.3 (6.8-9.1) 8.0 (7.4-8.3)
HR (95% CI) 0.75 (0.28-2.00) 0.91 (0.56-1.49) 1.37 (0.49-3.79) 0.93 (0.63-1.39)
OS
mo. (95% CI) 13.5 (9.8-28.7) 12.2 (10.2-14.8) 17.5 (14.0-24.0) 15.6 (14.7-16.9) 13.5 (9.8-28.7) 17.5 (14.0-24.0) 12.2 (10.2-14.8) 15.6 (14.7-16.9)
HR (95% CI) 1.21 (0.44-3.36) 0.85 (0.50-1.44) 1.51 (0.52-4.42) 1.55 (1.03-2.33)
Pooled data set
PFS
number of patients 53 197 100 2713 53 100 197 2713
mo. (95% CI) 6.1 (5.6-7.7) 6.2 (6.0-6.9) 6.3 (5.8-7.4) 7.8 (7.4-8.1) 6.1 (5.6-7.7) 6.3 (5.8-7.4) 6.2 (6.0-6.9) 7.8 (7.4-8.1)
HR (95% CI) 0.95 (0.62-1.46) 1.32 (1.00-1.75) 1.07 (0.67-1.70) 1.34 (1.10-1.64)
OS
mo. (95% CI) 11.7 (9.9-14.4) 11.3 (10.3-12.5) 15.0 (13.1-18.0) 17.3 (16.7-18.1) 11.7 (9.9-14.4) 15.0 (13.1-18.0) 11.3 (10.3-12.5) 17.3 (16.7-18.1)
HR (95% CI) 1.05 (0.68-1.63) 1.22 (0.91-1.65) 1.51 (0.93-2.46) 1.94 (1.57-2.40)
NOTE: Statistically significant results are set in bold
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Abbreviations: PFS = progression-free survival, OS = overall survival, mo. = median PFS or OS time in months, HR = Hazard ratio, CI = confidence interval, dMMR = deficient mismatch repair, pMMR =
proficient mismatch repair, mt = mutant tumor, wt = wild-type tumor
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